Bio-Rad revenue was $2.55 b in FY, 2020 which is a (10.1%) year over year increase from the previous period.
Bio-Rad revenue breakdown by business segment: 51.3% from Clinical Diagnostics, 48.4% from Life Science and 0.3% from Other
Bio-Rad revenue breakdown by geographic segment: 33.7% from Europe, 39.5% from United States, 5.4% from Other (primarily Canada and Latin America) and 21.5% from Asia
Q3, 2021 | Q1, 2020 | FY, 2018 | Q3, 2020 | Q2, 2020 | Q1, 2019 | Q2, 2019 | Q2, 2021 | Q3, 2019 | Q1, 2021 | FY, 2020 | FY, 2019 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Clinical Diagnostics | $372.2 m | $340.3 m | $1.41 b | $322.2 m | $283.2 m | $334.1 m | $357.1 m | $380.2 m | $341.8 m | $358.5 m | $1.31 b | $1.41 b |
Other | $1.3 m | $4.1 m | $15.9 m | $1.1 m | $1.6 m | $4.2 m | $3.1 m | $1.5 m | $3.1 m | $1.8 m | $8.6 m | $13.8 m |
Life Science | $373.5 m | $227.2 m | $861.7 m | $324 m | $252.1 m | $215.7 m | $212.4 m | $334.2 m | $215.7 m | $366.5 m | $1.23 b | $885.9 m |
Q3, 2021 | Q1, 2020 | FY, 2018 | Q3, 2020 | Q2, 2020 | Q1, 2019 | Q2, 2019 | Q2, 2021 | Q3, 2019 | Q1, 2021 | FY, 2020 | FY, 2019 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Europe | $221.5 m | $195.7 m | $792 m | $220.9 m | $174 m | $185.9 m | $188.2 m | $229.1 m | $181.9 m | $247.7 m | $857.7 m | $770.3 m |
United States | $315.4 m | $229.5 m | $863.6 m | $250.4 m | $205.4 m | $226.1 m | $222.1 m | $274.6 m | $225.8 m | $271.4 m | $1 b | $899.1 m |
Other (primarily Canada and Latin America) | $38.9 m | $35 m | $138.3 m | $34 m | $28.5 m | $35.6 m | $35 m | $40.1 m | $32.2 m | $38.8 m | $136.6 m | $137.3 m |
Asia | $171.2 m | $111.4 m | $142 m | $129 m | $127.3 m | $172.1 m | $120.7 m | $168.9 m | $546.5 m | $505 m | ||
Pacific Rim | $495.5 m | $106.4 m |
Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.